Sofosbuvir–Velpatasvir Fixed Drug Combination for the Treatment of Chronic Hepatitis C Infection in Patients With End-Stage Renal Disease and Kidney Transplantation

Efficacy and safety of sofosbuvir in the treatment of hep C among patients on hemodialysis: a systematic review and meta-analysis

“…The included studies were published from 2015 to 2020 and contained extractable data on 514 patients enrolled from 2014 to 2016. Four studies were retrospective [10][11][12][13] and 16 were prospective [14][15][16][17][18][19][20][21][22][23][24][25][26][27][28][29] . Nine of the studies were conducted in India 10,12,14,16,18,20,22,25,29 , 2 in the USA 15,21 , 2 in Pakistan 24,28 , 2 in China 19,27 , 1 in France 17 , the Czech Republic 11 , Korea 13 , Iraq 26 , and 1 enrolled patients from multiple countries 23 .…”

“…A total of 19 studies reported extractable data on the SOF dose [10][11][12][13][14][16][17][18][19][20][21][22][23][24][25][26][27][28][29] and the other DAA included in the treatment regimen. In nine studies [10][11][12][13]16,19,[21][22][23] , the same treatment regimen was used for all study participants. Six studies partitioned the study participants into subgroups and followed a different treatment strategy for each subgroup 14,17,18,20,24,25 .…”

“…A sub-group analysis was not performed for the various other DAA used in the treatment regimens, due to the large variability of DAA used. Ribavirin was used in 6 studies 10,13,14,16,18,28 , simeprevir in 3 15,17,21 , ledipasvir in 8 17,[20][21][22][25][26][27]29 , daclatasvir in 9 10,11,14,[16][17][18][19][20][24][25][26][27][28][29] and velpatasvir in 2 studies 12,23 (Table 1).…”

“…A total of 16 studies reported extractable data on adverse events [10][11][12][13][14][16][17][18][19][21][22][23]25,[27][28][29] ( Table 2). The most commonly reported adverse events were anemia (10 studies) 10,[12][13][14][16][17][18]21,23,28 , headache (8 studies) 12,17,[21][22][23]25,27,29 , fatigue (6 studies) 13,16,17,19,23,25 , nausea or vomiting (5 studies) 19,21,23,25,29 , insomnia (5 studies) 13,19,21,23,29…”

“… 26 2017 Prospective Iraq 19 54.8 63% GT-1a:100 DCV, LDV 200 mg daily, 400 mg daily 19 (100%) Gaur et al . 12 2017–2018 Retrospective India 31 39.8 77.5% GT-1: 67.7, GT-3: 32.2 VPV 400 mg daily 30 (97%) Cheema et al . 24 2017–2018 Prospective Pakistan 36 47.22 Group 1 53.89 Group 2 61.1% GT-1: 33.3, GT-2: 2.8, GT-3: 63.9 DCV 400 mg daily (Group 1), 400 mg 3 times/week (Group 2) 29 (80%) NR Not reported, GT genotype, SVR12 sustained virologic response 12 weeks after treatment, AD alternate day, RBV ribavirin, SMV simeprevir, LDV ledipasvir, DCV daclatasvir, VPV velpatasvir.…”